GL1X · GenesisL1 explorer

Research workbench

Linked KDM5A jmj domain bound to the inhibitor N19 [2-(5-((4-chloro-2- METHYLBENZYL)OXY)-1H-pyrazol-1-YL)ISONICOTINIC acid]

Analyse Linked KDM5A jmj domain bound to the inhibitor N19 [2-(5-((4-chloro-2… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
5IW0
Type
protein
Length
306 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Lysine-specific demethylase 5A
EC
1.14.11.-
UniProt
P29375
Ligands
6EP, AKG, MN
Pockets
3 · best druggability 0.67

Structure

x-ray diffraction · 1 distinct chain · 32% helix, 23% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ALysine-specific demethylase 5A (EC 1.14.11.-)protein30632% helix, 23% strandP29375

Ligands and binding sites

  • 6EP · 2-{5-[(4-chloro-2-methylphenyl)methoxy]-1H-pyrazol-1-yl}pyridine-4-carboxylic acid · ligand · chains A
  • AKG · 2-oxoglutaric acid · ligand · chains A
  • MN · Manganese (II) ion · metal · chains A
  • EDO · 1,2-ethanediol · additive · 2 copies · chains A
  • GOL · Glycerol · additive · 2 copies · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

3 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
14150.670.79506EP, AKG, MN, GOL
2510.380.8117empty
3830.380.7719EDO

Compared structures

  • 5IW0 · Linked KDM5A Jmj Domain Bound to the Inhibitor N19… · the same entry in another collection · chain A against A, TM-score 1.00
  • P29375 · AlphaFold monomer V2.0 prediction for lysine-specific demethylase 5A (P29375) · a predicted model of the same protein · chain A against A, TM-score 0.93

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.